• In May 2026, Xeris Biopharma Holdings reported first-quarter 2026 results showing revenue of US$83,130,000 versus US$60,120,000 a year earlier, returning to profitability with net income of US$2,230,000 and raising its full-year 2026 revenue guidance to US$380,000,000–US$390,000,000.
• An interesting aspect of this update is that stronger-than-expected momentum from Recorlev not only supported higher guidance but also underpinned a swing from loss to positive earnings per share.
• Next, we will examine how the upgraded 2026 revenue guidance and Recorlev momentum reshape Xeris Biopharma Holdings’ existing investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Xeris Biopharma Holdings Investment Narrative Recap

To own Xeris Biopharma, you need to believe its small portfolio can keep gaining traction fast enough to cover high commercial and R&D spending. The Q1 2026 profit and raised revenue guidance support that view in the near term, but they do not remove the core risk that dependence on Recorlev, Gvoke, and Keveyis could hurt results if competition or pricing pressure intensifies.

The most relevant recent announcement here is the upgraded 2026 revenue guidance to US$380,000,000 to US$390,000,000, supported by Recorlev’s stronger momentum. This guidance update directly ties into the key catalyst of expanding the commercial footprint in underserved endocrine markets, while also sharpening the contrast with risks around rising costs and concentration in a few products.

Yet against this encouraging update, investors should still be aware of the concentration risk around Recorlev and a few core therapies if...

Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from $-32.0 million today.

Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value, a 79% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$602,000,000 in 2029 revenue and much higher margins, which is a far more bullish view than consensus and may change meaningfully after this latest guidance raise.

Explore 3 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth just $11.14!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.